Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Madrigal Pharmaceuticals Inc (NQ: MDGL )

135.10 -5.69 (-4.04%)
Streaming Delayed Price Updated: 1:20 PM EDT, Oct 4, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 286,719
Open 141.00
Bid (Size) 134.76 (4)
Ask (Size) 135.41 (4)
Prev. Close 140.79
Today's Range 134.00 - 141.00
52wk Range 57.21 - 322.67
Shares Outstanding 17,103,395
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Nike, Carnival And 3 Stocks To Watch Heading Into Friday
With U.S. stock futures trading higher this morning on Friday, some of the stocks that may grab investor focus today are as follows: 
Via Benzinga
Nike, Carnival, Activision Blizzard, Madrigal Pharmaceuticals, Tesla: Why These 5 Stocks Are On Investors' Radars Today?
U.S. stocks traded higher with the Dow Jones gaining over 110 points on Thursday. The Dow traded up 0.35% to 33,666.34 while the NASDAQ rose 0.83% to 13,201.28. 
Via Benzinga
Topics Stocks
Exposures US Equities

Performance

YTD
-52.66%
-52.66%
1 Month
-26.77%
-26.77%
3 Month
-38.89%
-38.89%
6 Month
-43.84%
-43.84%
1 Year
+108.59%
+108.59%

More News

Read More
Wall Street Thinks Madrigal Pharmaceuticals Could Climb 93%. Here's Why It Could Happen Soon.
Via The Motley Fool
Investors Eye CymaBay's AFFIRM Study As Regulatory Uncertainties Ease
Via Benzinga
1 Beaten-Down Stock That Could Soar by 86%, According to Wall Street
Via The Motley Fool
Madrigal Pharmaceuticals Inc. (NASDAQ: MDGL) is a Leading Gainer in 9/13 Morning Trading
Via Investor Brand Network
The Latest Analyst Ratings for Madrigal Pharmaceuticals
Via Benzinga
Why Madrigal Pharmaceuticals Stock Is Marching Higher Today
Via The Motley Fool
Madrigal Pharmaceuticals Surges As Its NASH Treatment Toes The Long-Awaited Finish Line
Via Investor's Business Daily
Smucker, FuelCell Energy, Granite Ridge Resources And Other Big Stocks Moving Lower On Monday
Via Benzinga
Topics Stocks
Exposures US Equities
The 3 Best Biotech Stocks to Buy Now: September 2023
Via InvestorPlace
3 Biotech Stocks That Wall Street Analysts Can’t Get Enough Of
Via InvestorPlace
The 3 Most Promising Pharma Stocks to Own Now
Via InvestorPlace
3 Biotechs Compete for the Same $108-Billion-Dollar Market. Are They a Buy?
Via The Motley Fool
Looking for the Next Big Biopharma Stock? These 4 Letters Are 1 Big Clue Where to Find It
Via The Motley Fool
Ozempic Could Have a New Multibillion-Dollar Market Opportunity. Is Novo Nordisk Stock a No-Brainer Buy?
Via The Motley Fool
Madrigal Stock Pops As It Makes Inroads Into What Could Be A $160 Billion Market
Via Investor's Business Daily
Terns Pharmaceuticals Is "Attractively Priced" Despite Pressure From Eli Lilly's Obesity Data, Analyst Says
Via Benzinga
Why Walgreens Shares Are Trading Lower By Over 9%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
Via Benzinga
2 Growth Stocks That Doubled in 2023 and Could Shoot 55% to 87% Higher, According to Wall Street
Via The Motley Fool
10 Health Care Stocks Whale Activity In Today's Session
Via Benzinga
Madrigal Pharmaceuticals Inc. (NASDAQ: MDGL) Making Surprising Moves in Tuesday Session
Via Investor Brand Network
Intercept Crashes As FDA Advisors Deliver The Likely Deathblow For Its Highly Watched NASH Drug
Via Investor's Business Daily
Why These 3 Nasdaq Stocks Buckled Today
Via The Motley Fool
Viking Therapeutics Outperforms Expectations: Analyst Increases Price Target Following Successful VK2809 Trial
Via Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.